BioSig Technologies to Partner with Focus Marketing

Santa Monica, CA, Feb. 22, 2018 -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company appointed Focus Marketing to assist BioSig’s commercial team in preparation for the targeted launch of its PURE EP™ System. 

California based Focus Marketing is a boutique consulting firm with deep experience in electrophysiology.  Led by two former Biosense Webster marketers, the company delivers both strategic marketing guidance and tactical execution support for the healthcare and technology sectors.

Mrs. Cortney Donaldson, the company’s Founder and Principal Consultant, brings over 15 years of marketing and sales experience, having worked with a number of Fortune 50 companies on the development of new product plans and sales support execution. Prior to starting Focus Marketing, Mrs. Donaldson held a number of leadership roles, including Group Product Director at Biosense Webster, in which she was responsible for strategic company partnerships as well as the ultrasound and diagnostic product lines.

Ms. Carolyne MacLellan, the company’s Strategic Marketing Consultant, has extensive experience in clinical, sales and marketing roles at Biosense Webster, working directly with the key opinion leaders within the cardiac electrophysiology field. A cardiovascular technologist by training, she has successfully developed and launched a number of electrophysiology projects, including a global brand refresh for the CARTO^® 3 system and CONFIDENSE™ and CARTOREPLAY™ modules in the U.S. market.     

“The Focus Marketing Team has extensive history of successfully introducing technology in the EP space and we are excited about our new partnership with BioSig Technologies. The PURE EP™ System can bring a new level of signal clarity to electrophysiologists and has the potential to influence the treatment of AF and VT in meaningful ways,” commented Ms. MacLellan and Mrs. Donaldson.

“High quality marketing strategy and support is essential for a commercial launch. Cortney and Carolyne have impressed us with their remarkable track record in building clinical relations, commercialization, and their knowledge of electrophysiology. We are pleased to welcome them, and we are confident that our shareholders will benefit from their capabilities,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.

The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP™ System.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 

Contact:
Natasha Russkina
BioSig Technologies, Inc. 
VP Business Development & Corporate Finance 
[email protected]
+41 (0) 76 823 7527